… Semaglutide is protected by multiple patents that cover its formulation, … -release versions, seek additional patent protections to extend commercial viability … Viking Therapeutics Lexicon Pharmaceuticals Biocon AstraZeneca Key Attributes: Report Attribute …

… considered “marketed” under the statute.  AstraZeneca also challenged the Program itself … AstraZeneca argued the Negotiation Program deprived the company of its protected patent … , stating AstraZeneca owned no such property rights, as federal patent law does …

… Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche … acquisitions, mergers, licensing patent details, and other information … Pharmaceuticals, Inc. Quetiapine: AstraZeneca Reclaim®: MedtronicNeuro Bitopertin: Hoffmann …

… vice president, biopharmaceuticals business unit, AstraZeneca, said: “The UK approval of … propellant, HFA-134a. Developed and patented by Honeywell, the medical grade … . Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease …

… infertility. This composition of matter patent now positions Conduit to potentially … inhibitor, was originally developed by AstraZeneca for multiple sclerosis and chronic … medical unmet need. “This new patent application represents a meaningful advance …

… infringement of its Indian species patent (IN334397) covering the compound risdiplam … the court’s findings in AstraZeneca & Another v Intas Pharmaceutical … difference between the suit patent and genus patent WO’916 is that …

… Wednesday. As at 1100 BST, AstraZeneca – the FTSE 100’s biggest … using the active ingredients of patented drugs. Russ Mould, investment director … heaped pressure on GSK and AstraZeneca.”

… patent. Reference was made to the Division Bench judgement in Astrazeneca … with the Canadian genus patent regarding patent rights over Risdiplam. … 7] as well as Astrazeneca AB and Others Versus P … on the judgement in Astrazeneca AB and Another Versus …

… ahead. Ticagrelor (Brilinta; AstraZeneca) Ticagrelor (Brilinta; AstraZeneca) was originally launched with … after the patent expiration of rosuvastatin (Crestor; AstraZeneca).1 Approved … strategy, curtailed growth. Although AstraZeneca once targeted $3.5 …

… the company and its alleged patent misuse in court. Soliris … with a 14-year patent that was set to … later added five “fraudulent” extra patents through "deceptive" … EmblemHealth alleges in the complaint. AstraZeneca cannot comment on the litigation …